Shares of Doximity (DOCS), the operator of a digital platform for U.S. medical professionals, are trading up $2.11, or 4%, to $58.07 after Rachel Cohrs Zhang of Bloomberg reported, citing sources, that the Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients. The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad, likely making broadcast ads much longer and prohibitively expensive, or removing the industry’s ability to deduct direct-to-consumer advertising as a business expense for tax purposes, sources said. Doximity, which says its mission is to “help doctors be more productive so they can provide better care for their patients,” provides its verified clinical membership with digital tools built for medicine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity Co-Founder Steps Down to Advisory Role
- “Demand…Will Continue to Rise”: Doximity Stock (NYSE:DOCS) Slips Despite Analyst Love
- Boeing upgraded, PayPal initiated: Wall Street’s top analyst calls
- Doximity’s Hold Rating: Navigating Growth Amid Biopharma Advertising Uncertainties
- Doximity upgraded to Buy from Neutral at BTIG